Real-world effectiveness of switching to fremanezumab from other CGRP pathway targeting mAbs: PEARL 3rd interim analysis

被引：0
|
作者：
Ashina, M. [1 ,2 ]
Mitsikostas, D. [3 ]
Amin, F. [1 ,4 ]
Kokturk, P. [5 ]
Schankin, C. [6 ]
Sahin, G. [7 ]
Pozo-Rosich, P. [8 ,9 ,10 ]
Dorman, P. [11 ]
Nezadal, T. [12 ]
Poole, A. [13 ]
Martins, I. [14 ]
Sumelahti, M. [15 ]
Campos, V. Ramirez [16 ]
Ning, X.
Akcicek, H.
Tassorelli, C. [17 ,18 ]
机构：
[1] Copenhagen Univ Hosp, Rigshosp Glostrup, Danish Headache Ctr, Dept Neurol, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Natl & Kapodistrian Univ Athens, Aeginition Hosp, Dept Neurol 1, Athens, Greece
[4] Univ Copenhagen, Rigshosp Glostrup, Dept Neurorehabil Traumat Brain Injury, Copenhagen, Denmark
[5] Teva Netherlands BV, Amsterdam, Netherlands
[6] Univ Bern, Univ Hosp Bern, Dept Neurol, Inselspital, Bern, Switzerland
[7] Lund Univ, Dept Clin Sci Lund, Skaneuro Neurol Clin, Lund, Sweden
[8] Univ Autonoma Barcelona, Vall dHebron Hosp, Headache Unit, Barcelona, Spain
[9] Univ Autonoma Barcelona, Vall dHebron Hosp, Res Grp, Barcelona, Spain
[10] Univ Autonoma Barcelona, Res Inst, Barcelona, Spain
[11] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle, England
[12] Charles Univ Prague, Sch Med 1, Inst Neuropsychiat Care, Prague, Czech Republic
[13] Oslo Headache Ctr, Oslo, Norway
[14] Univ Lisbon, Fac Med, Ctr Estudos Egas Moniz, Lisbon, Portugal
[15] Univ Tampere, Fac Med & Hlth Technol, Tampere, Finland
[16] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[17] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy
[18] IRCCS Mondino Fdn, Pavia, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-075
引用
收藏
页码：371 / 372
页数：2
相关论文
共 50 条
  • [1] Real-world effectiveness & safety of fremanezumab in migraine: 3rd interim analysis of the pan-European PEARL study
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Lyras, L.
    Tassorelli, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 149 - 150
  • [2] Real-World effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-european PEARL study
    Ashina, M.
    Mitsikostas, D. D.
    Amin, F. Mohammad
    Kokturk, P.
    Schankin, C. J.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A. Christine
    Martins, I. Pavao
    Sumelahti, M. L.
    Campos, V. Ramirez
    Ning, X.
    Lyras, L.
    Tassorelli, C.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [3] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [4] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Andreas Straube
    Gregor Broessner
    Charly Gaul
    Xenia Hamann
    Joachim Hipp
    Torsten Kraya
    Lars Neeb
    [J]. The Journal of Headache and Pain, 24
  • [5] Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Schauerte, Isabel
    Neeb, Lars
    [J]. NEUROLOGY, 2023, 100 (17)
  • [6] Real-world effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Schauerte, I
    Neeb, L.
    [J]. HEADACHE, 2023, 63 : 158 - 159
  • [7] 6-month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 260 - 260
  • [8] 6-Month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Neeb, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [9] Impact of fremanezumab on headache intensity and duration of remaining migraine attacks: PEARL 3rd interim analysis
    Tassorelli, C.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Krasenbaum, L.
    Ahn, A.
    Akcicek, H.
    Ashina, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 690 - 690
  • [10] Switching from anti-CGRP-receptor mAb (erenumab) to an antiCGRP-molecule mAbs (fremanezumab) in chronic migraine: results of a real-world study
    Caponnetto, V.
    Hill, B.
    Murphy, M.
    Ighavini, O.
    Briscoe, J.
    Arruda, R.
    Andreou, A. P.
    Lambru, G.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
12345